The technology Anaxomics has developed based on artificial intelligence (AI) has been used in a ground-breaking study by the Barcelona Institute for Global Health, which has revealed that the efficacy of malaria vaccines can be predicted using molecular biomarkers. The results have been published in Science Translational Medicine.

Additionally, Anaxomics has also recently worked with the Immunology of Diabetes Group at the Institute for Health Science Research Germans Trias i Pujol (IGTP), which is researching a drug that reprograms pancreatic cells in rats with type-1 diabetes. This drug was selected using AI as the best candidate from a list of 6,605 drugs already approved. The research has been published in Frontiers in Endocrinology.

The Anaxomics technology is called the Therapeutic Performance Mapping System (TPMS) and is rated highly by researchers for using AI to simulate human physiology and how drugs interact. So far, it has been used by over 70 pharmaceutical companies (Pfizer, Novartis, Roche, Sobi, etc.) and hospitals (Clinic, Dotze d’Octubre, Germans Trias i Pujol, Vall d’Hebron, etc.).

Anaxomics i a CataloniaBio & HealthTech member.

Photo: Mireia Coma, Business Development Director at Anaxomics.

You may also be interested in:

Anaxomics inaugurates headquarters in Barcelona to continue growth in 2020